Abecma’s US Revenue Decreased; FDA Formally Puts DARIC33’s Trial on Hold; Manufacturing Capacity Ramping Up; 2seventy bio Q2 2023 Earnings Call Summary
On Monday, August 14, 2seventy bio held its Q2 2023 earnings call (press release) acknowledging Abecma’s (BMS / 2seventy’s BCMA CAR-T) decline in US sales while disclosing updates on the SC-DARIC33’s (drug-regulated CD33 CAR-T) Ph1 PLAT-08 clinical hold. Below, Celltelligence provides insights on the causes behind Abecma’s revenue decrease while discussing the potential delay that the clinical hold might cause on DARIC33’s clinical development.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.